Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Income towards Parent Company (2016 - 2025)

Sunshine Biopharma's Income towards Parent Company history spans 12 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 16.86% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $1.2 million, down 9.43%, while the annual FY2025 figure was $1.2 million, 9.43% down from the prior year.
  • Income towards Parent Company reached $5.1 million in Q4 2025 per SBFM's latest filing, up from -$883820.0 in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $5.1 million in Q4 2025 to a low of -$23.5 million in Q4 2022.
  • Average Income towards Parent Company over 5 years is -$2.1 million, with a median of -$1.2 million recorded in 2022.
  • Peak YoY movement for Income towards Parent Company: crashed 3624.47% in 2022, then soared 446.59% in 2024.
  • A 5-year view of Income towards Parent Company shows it stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then skyrocketed by 446.59% to $4.3 million in 2024, then rose by 16.86% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Income towards Parent Company are $5.1 million (Q4 2025), -$883820.0 (Q3 2025), and -$1.8 million (Q2 2025).